<code id='106D72F49B'></code><style id='106D72F49B'></style>

<acronym id='106D72F49B'></acronym>

<center id='106D72F49B'><center id='106D72F49B'><tfoot id='106D72F49B'></tfoot></center><abbr id='106D72F49B'><dir id='106D72F49B'><tfoot id='106D72F49B'></tfoot><noframes id='106D72F49B'>

<optgroup id='106D72F49B'><strike id='106D72F49B'><sup id='106D72F49B'></sup></strike><code id='106D72F49B'></code></optgroup>

<b id='106D72F49B'><label id='106D72F49B'><select id='106D72F49B'><dt id='106D72F49B'><span id='106D72F49B'></span></dt></select></label></b><u id='106D72F49B'></u>

~~<i id='106D72F49B'><strike id='106D72F49B'><tt id='106D72F49B'><pre id='106D72F49B'></pre></tt></strike></i>~~

explore

author entertainment

2025-10-02 11:43:43

Alexis Borisy — Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hospitals struggle to profit from CAR
Next article： Medical records are filled with copy

Tags

Leave your comment

fashion

7 more heat

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

2025-10-02 10:10

Vir antibody drug aimed at influenza A fails in clinical trial

Wikipedia

Apple is now the first public company to be valued at $3 trillion

2025-10-02 11:35

Venture capitalist Bob Kocher on the state of digital health

fashion

Jerome Adams on the need for new antivirals for Covid

2025-10-02 10:33

Tesla recalling nearly 16,000 of its 2021

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

2025-10-02 09:25